Synthesis and analysis of the quality of the substance of 7,8-dihydro-3,7,7-trimethyl-4-styryl-2H-pyrazolo[3,4-b]quinolin-5(4H,6H,9H)-one – a new biologically active compound with complex antidiabetic action.

doi:10.26565/2220-637X-2017-29-05

Nаtalya I. Zemlyanaya State Institution Danilevskii Institute for Endocrine Pathology Problems, National Academy of Medical Sciences of Ukraine https://orcid.org/0000-0003-4037-4341
S. V. Kravchenko State Institution Danilevskii Institute for Endocrine Pathology Problems, National Academy of Medical Sciences of Ukraine
Ludmila E. Nikishina State Institution Danilevskii Institute for Endocrine Pathology Problems, National Academy of Medical Sciences of Ukraine
Victoria V. Lipson State Institution Danilevskii Institute for Endocrine Pathology Problems, National Academy of Medical Sciences of Ukraine https://orcid.org/0000-0003-0922-1785

DOI: https://doi.org/10.26565/2220-637X-2017-29-05

Keywords: three-component cyclocondensation, 3-methylpyrazol-5-amine, 5,5-dimethylcyclohexane-1,3-dione, 3-phenylprop-2-enal, analytical quality assessment, solubility, chromatographic purity, antidiabetic activity

Abstract

A method for the synthesis of potential inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 – 7,8-dihydro-3,7,7-trimethyl-4-styryl-2H-pyrazolo[3,4-b]quinolin-5(4H,6H,9H)-one, methods for the control of concomitant impurities and the quantitative content of the main substance in the samples of the compound intended for an expanded pharmacological study of specific antidiabetic properties in experimental animal models of type 2 diabetes mellitus accompanied by obesity were developed.

Downloads

Download data is not yet available.

References

Diagnosis and classification of diabetes mellitus / American Diabetes Association // Diabetes Care. – 2012. – Vol. 35, Suppl. 1. – P. S64-S71.

International Diabetes Federation. Diabetes Atlas, 6th edition, Brussels, Belgium: Interna-tional Diabetes Federation, 2013.

Day C. Metabolic syndrome, or what you will: definitions and epidemiology // Diabetes Vasc. Dis. Res. – 2007. – Vol. 4. – P. 32-38.

Bays H. E., Chapman R. H., Grandy S. The relationship of body mass index to diabetes melli-tus, hypertension and dyslipidaemia: comparison of data from two national surveys // Int. J. Clin. Pract. – 2007. – Vol. 61. – P. 737-747.

Stewart P. M. Tissue-specific Cushing's syndrome uncovers a new target in treating the meta-bolic syndrome – 11-beta-hydroxysteroid dehydrogenase type 1 // Clin. Med. – 2005. – Vol. 5. – P. 142-146.

Fotsch C., Wang M. Blockade of glucocorticoid excess at the tissue level: inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes // J. Med. Chem. – 2008. – Vol. 51. – P. 4851-4857.

Hughes K. A., Webster S. P., Walker B. R. 11-Beta-hydroxysteroid dehydrogenase type 1 (11β -HSD1) inhibitors in type 2 diabetes mellitus and obesity // Expert Opin. Investig. Drugs. – 2008. – Vol. 17. – P. 481-496.

Webster S. P., Pallin T. D. 11-β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeu-tic agents // Expert Opin. Ther. Patents. – 2007. – Vol. 17. – P. 1407-1422.

Boyle C. D., Boyle C. D., Kowalski T. J. 11β-Hydroxysteroid dehydrogenase type 1 inhibi-tors: a review of recent patents // Expert Opin. Ther. Patents. – 2009. – Vol. 19. – P. 801-825.

Ge R., Huang Y., Liang G., Li X. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development // Curr. Med. Chem. – 2010. – Vol. 17. – P. 412-422.

Zemlyanaya N.I., Borodina V.V., Musatov V.I., Shishkina S.V., Sofronov D.S., Lipson V.V. Cyclocondensations of 3-alkylpyrazol-5-amines with 3-arylprop-2-enals and cyclic 1,3-diketones / Russ. J. Org. Chem. – 2017. – Vol. 53. – P. 582-591.

Krasova N.S., Gladkih A.I., Leschenko J.A., Tizhnenko T.V., Opaleiko J.A., Zubatuk T.A., Lipson V.V., Poltorack V.V. Efekt potenciynogo ingibitora 11-beta-gidroksisteroiddegidrogenazi 1 tipu na funkcionalno-metabolichni pokazniki schuriv z eksperimentalnim cukrovim diabetom // Endokrinologiya. – 2014. – T.19. – S.314.

Derjavna Farmakopeya Ukrai`ni / Derjavne pi'dprie''mstvo “Naukovo-ekspertniy farmako-peyniy centr”. – 1-e vid. – H. : RI'REG, 2001. – 556 s.